BDA-366|BDA366|Bcl2-BH4 Antagonisten

Page 1

Website:www.dcchemicals.com Email: info@dcchemicals.com Phone:+86-21-58447131 Marketing Center: Room 610,Building 15, Jinxiang Rd 201, Shanghai, China

Datasheet of BDA-366

Description: BDA-366 is a small-molecule Bcl2-BH4 domain antagonist, BDA-366, that binds BH4 with high affinity and selectivity. BDA-366-Bcl2 binding induces conformational change in Bcl2 that abrogates its antiapoptotic function, converting it from a survival molecule to a cell death inducer. BDA-366 suppresses growth of lung cancer xenografts derived from cell lines and patient without significant normal tissue toxicity at effective doses. mTOR inhibition upregulates Bcl2 in lung cancer cells and tumor tissues from clinical trial patients. Combined BDA-366 and RAD001 treatment exhibits strong synergy against lung cancer in vivo. \Chemical

Information

Catalog

DC9709

Purity of current batch:

>98%

Molecular Weight (MW)

423.5

Molecular Formula

C24H29N3O4

CAS No.

1821496-27-8

Solubility (25°C)

DMSO

Storage

Store at -20°C (desiccating conditions).

Handling: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months. Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.